Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Riot Blockchain, Inc.ex99x1.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported) December 21, 2012
 
   
Venaxis, Inc.
 
 
   
(Exact name of Registrant as specified in its charter)
   
  
Colorado
 
001-33675
 
84-1553387
(State or other jurisdiction of incorporation or organization)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)
 
1585 South Perry Street
Castle Rock, Colorado
 
80104
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code:
 
(303) 794-2000
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 

 
Item 8.01.  Other Events.
 
On December 21, 2012, Venaxis, Inc., (formerly AspenBio Pharma, Inc.) (the “Company”) issued a press release titled — “Venaxis Files for CE Mark and Prepares for European Commercialization.”  The press release is filed as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibits
 
99.1
Press Release of Venaxis, Inc. titled “Venaxis Files for CE Mark and Prepares for European Commercialization,” issued December 21, 2012.

 
 
 
 
 

 
 

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

         
 
Venaxis, Inc.
(Registrant)
 
 
December 21, 2012
By:  
 /s/ Jeffrey G. McGonegal  
 
   
Name:  
Jeffrey G. McGonegal
 
   
Title:  
Chief Financial Officer